Skip to Content

'
Ana Maria Gonzalez-Angulo, M.D., M.Sc., F.A.C.P.

Present Title & Affiliation

Primary Appointment

Associate Professor (with Tenure), Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Chief, Section of Clinical Research and Drug Development, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Dual/Joint/Adjunct Appointment

Associate Professor (with Tenure), Department of Systems Biology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Bio Statement

Dr. Gonzalez-Angulo, attended medical school at the Universidad del Cauca in Colombia and moved to the U.S. to continue her training. She completed a residency in Internal Medicine at the Mount Sinai Medical Center in Miami, and a Fellowship in Medical Oncology at the Ochsner Clinic Foundation in New Orleans. She then went to the University of Texas MD Anderson Cancer Center to specialize in Breast Cancer as she was selected as the Susan G. Komen Breast Cancer Fellow. She stayed at MD Anderson faculty and works exclusively with Breast Cancer patients and in Breast Cancer research.

She is interested in aggressive types of breast cancer including triple receptor-negative disease. Her research focuses on mechanisms of resistance to standard breast cancer therapies, and on the development of markers to predict response to treatments using functional proteomics. She is funded by the NCI, ASCO, Komen for the Cure, AACR (SU2C) and the Commonwealth Foundation for Cancer research.

She is the Chair of the Endocrine Resistance Working Group and a member of the Correlative Sciences Working Group for the Translational Breast Cancer Research Consortium, and a member of the Breast Cancer Committee of SWOG and of the BIG-NABG Triple Negative Working Group. She serves as a member of the steering committee of The United States – Middle East Partnership for Breast Cancer Awareness and Research and the Partnership for Breast Cancer Awareness and Research of the Americas.

Office Address

The University of Texas MD Anderson Cancer Center
1515 Holcombe Blvd.
Breast Medical Oncology
Unit Number: Unit 1354
Houston, TX 77030-4009
Phone: (713) 792-2817
Fax: (713) 794-4385
Email: agonzalez@mdanderson.org

Education & Training

Degree-Granting Education

2007 The University of Texas Health Science Center, Houston, TX, M.Sc., Translational Research Sciences
1995 Universidad del Cauca School of Medicine, Popayan, Colombia, MD, Physician and Surgeon

Postgraduate Training

7/2003-6/2004 Fellow, Susan G. Komen Interdisciplinary Breast Cancer, The University of Texas MD Anderson Cancer Center, Houston, TX, Gabriel N. Hortobagyi, M.D.
7/2001-6/2003 Fellow, Medical Oncology, Ochsner Clinic Foundation, New Orleans, LA, John T. Cole, M.D.
7/1999-6/2001 Resident, Internal Medicine, Mount Sinai Medical Center, Miami Beach, FL, Gloria B. Weinberg, M.D.
6/1998-6/1999 Intern, Internal Medicine, Mount Sinai Medical Center, Miami Beach, FL, Gloria B. Weinberg, M.D.

Board Certifications

11/2003 ABIM-Diplomat, Medical Oncology
8/2001 ABIM-Diplomat, Internal Medicine

Selected Publications

Peer-Reviewed Original Research Articles

1. Gonzalez-Angulo AM, Chen H, Karuturi MS, Chavez-MacGregor M, Tsavachidis S, Meric-Bernstam F, Do KA, Hortobagyi GN, Thompson PA, Mills GB, Bondy ML, Blumenschein GR. Frequency of mesenchymal-epithelial transition factor gene (MET) and the catalytic subunit of phosphoinositide-3-kinase (PIK3CA) copy number elevation and correlation with outcome in patients with early stage breast cancer. Cancer 119(1):7-15, 1/1/2013. e-Pub 6/26/2012. PMCID: PMC3461089.
2. Kim MM, Dawood S, Allen P, Sahin AA, Woodward WA, Smith BD, Strom EA, Hunt KK, Meric-Bernstam F, Gonzalez-Angulo AM, Buchholz TA. Hormone Receptor Status Influences the Locoregional Benefit of Trastuzumab in Patients with Non-metastatic Breast Cancer. Cancer 118(20):4936-43, 10/15/2012. e-Pub 4/17/2012. PMID: 22511276.
3. Lynch SP, Lei X, Chavez-Macgregor M, Hsu L, Meric-Bernstam F, Buchholz TA, Zhang A, Hortobagyi GN, Valero V, Gonzalez-Angulo AM. Multifocality and multicentricity in breast cancer and survival outcomes. Ann Oncol. e-Pub 7/9/2012. PMID: 22776706.
4. Santarpia L, Qi Y, Stemke-Hale K, Wang B, Young EJ, Booser DJ, Holmes FA, O'Shaughnessy J, Hellerstedt B, Pippen J, Vidaurre T, Gomez H, Valero V, Hortobagyi GN, Symmans WF, Bottai G, Di Leo A, Gonzalez-Angulo AM, Pusztai L. Mutation profiling identifies numerous rare drug targets and distinct mutation patterns in different clinical subtypes of breast cancers. Breast Cancer Res Treat 134(1):333-43, 7/2012. e-Pub 4/27/2012. PMID: 22538770.
5. Balko JM, Cook RS, Vaught DB, Kuba MG, Miller TW, Bhola NE, Sanders ME, Granja-Ingram NM, Smith JJ, Meszoely IM, Salter J, Dowsett M, Stemke-Hale K, González-Angulo AM, Mills GB, Pinto JA, Gómez HL, Arteaga CL. Profiling of residual breast cancers after neoadjuvant chemotherapy identifies DUSP4 deficiency as a mechanism of drug resistance. Nat Med 18(7):1052-9, 7/2012. e-Pub 6/10/2012. PMID: 22683778.
6. Dawood S, Shaikh AJ, Buchholz TA, Cortes J, Cristofanilli M, Gupta S, Gonzalez-Angulo AM. The use of bevacizumab among women with metastatic breast cancer: A survey on clinical practice and the ongoing controversy. Cancer 118(11):2780-6, 6/1/2012. e-Pub 10/5/2011. PMID: 22614656.
7. Moulder S, Gladish G, Ensor J, Gonzalez-Angulo AM, Cristofanilli M, Murray JL, Booser D, Giordano SH, Brewster A, Moore J, Rivera E, Hortobagyi GN, Tran HT. A phase 1 study of weekly everolimus (RAD001) in combination with docetaxel in patients with metastatic breast cancer. Cancer 118(9):2378-84, 5/1/2012. e-Pub 10/17/2011. PMID: 22006179.
8. Bayraktar S, Gonzalez-Angulo AM, Lei X, Buzdar AU, Valero V, Melhem-Bertrandt A, Kuerer HM, Hortobagyi GN, Sahin AA, Meric-Bernstam F. Efficacy of Neoadjuvant Therapy with Trastuzumab Concurrent with Anthracycline- and Non-anthracycline-based Regimens for HER2-Positive Breast Cancer. Cancer 118(9):2385-93, 5/1/2012. e-Pub 9/27/2011. PMCID: PMC3274632.
9. Raghav KP, Wang W, Liu S, Chavez-MacGregor M, Meng X, Hortobagyi GN, Mills GB, Meric-Bernstam F, Blumenschein GR, Gonzalez-Angulo AM. cMET and phospho-cMET protein levels in breast cancers and survival outcomes. Clin Cancer Res 18(8):2269-77, 4/15/2012. e-Pub 2/28/2012. PMID: 22374333.
10. Horiuchi D, Kusdra L, Huskey NE, Chandriani S, Lenburg ME, Gonzalez-Angulo AM, Creasman KJ, Bazarov AV, Smyth JW, Davis SE, Yaswen P, Mills GB, Esserman LJ, Goga A. MYC pathway activation in triple-negative breast cancer is synthetic lethal with CDK inhibition. J Exp Med 209(4):679-96, 4/9/2012. e-Pub 3/19/2012. PMCID: PMC3328367.
11. Morrow PK, Serna R, Broglio K, Pusztai L, Nikoloff DM, Hillman GR, Fontecha M, Li R, Michaud L, Hortobagyi G, Gonzalez-Angulo AM. Effect of CYP2D6 polymorphisms on breast cancer recurrence. Cancer 118(5):1221-7, 3/1/2012. e-Pub 8/5/2011. PMID: 21823108.
12. Bayraktar S, Hernadez-Aya LF, Lei X, Meric-Bernstam F, Litton JK, Hsu L, Hortobagyi GN, Gonzalez-Angulo AM. Effect of metformin on survival outcomes in diabetic patients with triple receptor-negative breast cancer. Cancer 118(5):1202-11, 3/1/2012. e-Pub 7/28/2011. PMCID: PMC3207034.
13. Raghav KP, Hernandez-Aya LF, Lei X, Chavez-Macgregor M, Meric-Bernstam F, Buchholz TA, Sahin A, Do KA, Hortobagyi GN, Gonzalez-Angulo AM. Impact of low estrogen/progesterone receptor expression on survival outcomes in breast cancers previously classified as triple negative breast cancers. Cancer 118(6):1498-506, 3/15/2012. e-Pub 8/11/2011. PMCID: PMC3217101.
14. Kelly CM, Green MC, Broglio K, Thomas ES, Brewster AM, Valero V, Ibrahim NK, Gonzalez-Angulo AM, Booser DJ, Walters RS, Hunt KK, Hortobagyi GN, Buzdar AU. Phase III Trial Evaluating Weekly Paclitaxel Versus Docetaxel in Combination With Capecitabine in Operable Breast Cancer. J Clin Oncol 30(9):930-5, 3/20/2012. e-Pub 2/13/2012. PMID: 22331946.
15. Meric-Bernstam F, Akcakanat A, Chen H, Do KA, Sangai T, Adkins F, Gonzalez-Angulo AM, Rashid A, Crosby K, Dong M, Phan AT, Wolff RA, Gupta S, Mills GB, Yao J. PIK3CA/PTEN Mutations and Akt Activation as Markers of Sensitivity to Allosteric mTOR inhibitors. Clin Cancer Res 18(6):1777-89, 3/15/2012. PMCID: PMC3307149.
16. Niikura N, Liu J, Hayashi N, Mittendorf EA, Gong Y, Palla SL, Tokuda Y, Gonzalez-Angulo AM, Hortobagyi GN, Ueno NT. Loss of Human Epidermal Growth Factor Receptor 2 (HER2) Expression in Metastatic Sites of HER2-Overexpressing Primary Breast Tumors. J Clin Oncol 30(6):593-9, 2/20/2012. e-Pub 11/28/2011. PMCID: PMC3295557.
17. Chavez-Macgregor M, Brown E, Lei X, Litton J, Meric-Bernstram F, Mettendorf E, Hernandez L, Valero V, Hortobagyi GN, Gonzalez-Angulo AM. Bisphosphonates and pathologic complete response to taxane and anthracycline-based neoadjuvant chemotherapy in patients with breast cancer. Cancer 118(2):326-32, 1/15/2012. e-Pub 5/16/2011. PMCID: PMC3158806.
18. Litton JK, Ready K, Chen H, Gutierrez-Barrera A, Etzel CJ, Meric-Bernstam F, Gonzalez-Angulo AM, Le-Petross H, Lu K, Hortobagyi GN, Arun BK. Earlier age of onset of BRCA mutation-related cancers in subsequent generations. Cancer 118(2):321-5, 1/15/2012. e-Pub 9/12/2011. PMID: 21913181.
19. Lester TR, Hunt KK, Nayeemuddin KM, Bassett RL, Gonzalez-Angulo AM, Feig BW, Huo L, Rourke LL, Davis WG, Valero V, Gilcrease MZ. Metaplastic sarcomatoid carcinoma of the breast appears more aggressive than other triple receptor-negative breast cancers. Breast Cancer Res Treat 131(1):41-8, 1/2012. e-Pub 2/18/2011. PMID: 21331622.
20. Park YY, Kim K, Kim SB, Hennessy BT, Kim SM, Park ES, Lim JY, Li J, Lu Y, Gonzalez-Angulo AM, Jeong W, Mills GB, Safe S, Lee JS. Reconstruction of nuclear receptor network reveals that NR2E3 is a novel upstream regulator of ESR1 in breast cancer. EMBO Mol Med 4(1):52-67, 1/2012. e-Pub 12/15/2011. PMCID: PMC3376834.
21. Bartholomeusz C, Gonzalez-Angulo AM, Liu P, Hayashi N, Lluch A, Ferrer-Lozano J, Hortobágyi GN. High ERK Protein Expression Levels Correlate with Shorter Survival in Triple-Negative Breast Cancer Patients. Oncologist 17(6):766-74, 2012. e-Pub 5/14/2012. PMCID: PMC3380875.
22. Caudle AS, Yu TK, Tucker SL, Bedrosian I, Litton JK, Gonzalez-Angulo AM, Hoffman K, Meric-Bernstam F, Hunt KK, Buchholz TA, Mittendorf EA. Local-regional control according to surrogate markers of breast cancer subtypes and response to neoadjuvant chemotherapy in breast cancer patients undergoing breast conserving therapy. Breast Cancer Res 14(3):R83, 2012. e-Pub 5/23/2012. PMCID: PMC3446346.
23. Yi M, Mittendorf EA, Cormier JN, Buchholz TA, Bilimoria K, Sahin AA, Hortobagyi GN, Gonzalez-Angulo AM, Luo S, Buzdar AU, Crow JR, Kuerer HM, Hunt KK. Novel staging system for predicting disease-specific survival in patients with breast cancer treated with surgery as the first intervention: time to modify the current American Joint Committee on Cancer staging system. J Clin Oncol 29(35):4654-61, 12/10/2011. e-Pub 11/14/2011. PMCID: PMC3236648.
24. Fox EM, Miller TW, Balko JM, Kuba MG, Sánchez V, Smith RA, Liu S, González-Angulo AM, Mills GB, Ye F, Shyr Y, Manning HC, Buck E, Arteaga CL. A kinome-wide screen identifies the Insulin/IGF-1 receptor pathway as a mechanism of escape from hormone dependence in breast cancer. Cancer Res 71(21):6773-6784, 11/1/2011. e-Pub 9/9/2011. PMCID: PMC3206206.
25. Nagar H, Mittendorf EA, Strom EA, Perkins GH, Oh JL, Tereffe W, Woodward WA, Gonzalez-Angulo AM, Hunt KK, Buchholz TA, Yu TK. Local-Regional Recurrence With and Without Radiation Therapy after Neoadjuvant Chemotherapy and Mastectomy for Clinically Staged T3n0 Breast Cancer. Int J Radiat Oncol Biol Phys 81(3):782-7, 11/1/2011. e-Pub 8/30/2011. PMID: 21885207.
26. Bayraktar S, Gutierrez-Barrera AM, Liu D, Tasbas T, Akar U, Litton JK, Lin E, Albarracin CT, Meric-Bernstam F, Gonzalez-Angulo AM, Hortobagyi GN, Arun BK. Outcome of triple-negative breast cancer in patients with or without deleterious BRCA mutations. Breast Cancer Res Treat 130(1):145-53, 11/2011. e-Pub 8/10/2011. PMID: 21830012.
27. Hu R, Peng G, Dai H, Breuer EK, Stemke-Hale K, Li K, Gonzalez-Angulo AM, Mills GB, Lin SY. ZNF668 functions as a tumor suppressor by regulating p53 stability and function in breast cancer. Cancer Res 71(20):6524-34, 10/15/2011. e-Pub 8/18/2011. PMCID: PMC3193577.
28. Theriault RL, Litton JK, Mittendorf EA, Chen H, Meric-Bernstam F, Chavez-MacGregor M, Morrow PK, Woodward WA, Sahin A, Hortobagyi GN, Gonzalez-Angulo AM. Age and Survival Estimates in Patients Who Have Node-Negative T1ab Breast Cancer by Breast Cancer Subtype. Clin Breast Cancer 11(5):325-31, 10/2011. e-Pub 7/2011. PMID: 21764391.
29. Adkins FC, Gonzalez-Angulo AM, Lei X, Hernandez-Aya LF, Mittendorf EA, Litton JK, Wagner J, Hunt KK, Woodward WA, Meric-Bernstam F. Triple-negative breast cancer is not a contraindication for breast conservation. Ann Surg Oncol 18(11):3164-73, 10/2011. e-Pub 9/27/2011. PMID: 21947595.
30. Durak MG, Gonzalez-Angulo AM, Hanrahan EO, Broglio KR, Valero V, Hortobagyi GN, Hunt KK, Sahin AA. Age and Associated Fibrocystic Changes are Prognostically Significant in Patients with Small Node-Negative (T1a,bN0) Invasive Breast Cancer. Breast J 17(5):462-9, Sep-Oct, 9/2011. e-Pub 7/5/2011. PMID: 21726347.
31. Miller TW, Balko JM, Fox EM, Ghazoui Z, Dunbier A, Anderson H, Dowsett M, Jiang A, Smith RA, Maira SM, Manning HC, González-Angulo AM, Mills GB, Higham C, Chanthaphaychith S, Kuba MG, Miller WR, Shyr Y, Arteaga CL. ERa-dependent E2F transcription can mediate resistance to estrogen deprivation in human breast cancer. Cancer Discov 1(4):338-351, 9/2011. e-Pub 7/20/2011. PMCID: PMC3204388.
32. Lara-Medina F, Pérez-Sánchez V, Saavedra-Pérez D, Blake-Cerda M, Arce C, Motola-Kuba D, Villarreal-Garza C, González-Angulo AM, Bargalló E, Aguilar JL, Mohar A, Arrieta Ó. Triple-negative breast cancer in hispanic patients: High prevalence, poor prognosis, and association with menopausal status, body mass index, and parity. Cancer 117(16):3658-69, 8/15/2011. e-Pub 3/8/2011. PMID: 21387260.
33. Dawood S, Ueno NT, Valero V, Woodward WA, Buchholz TA, Hortobagyi GN, Gonzalez-Angulo AM, Cristofanilli M. Identifying factors that impact survival among women with inflammatory breast cancer. Ann Oncol. e-Pub 7/15/2011. PMID: 21765048.
34. Pradeep CR, Köstler WJ, Lauriola M, Granit RZ, Zhang F, Jacob-Hirsch J, Rechavi G, Nair HB, Hennessy BT, Gonzalez-Angulo AM, Tekmal RR, Ben-Porath I, Mills GB, Domany E, Yarden Y. Modeling ductal carcinoma in situ: a HER2-Notch3 collaboration enables luminal filling. Oncogene. e-Pub 7/11/2011. PMID: 21743488.
35. Melhem-Bertrandt A, Chavez-MacGregor M, Lei X, Brown EN, Lee RT, Meric-Bernstam F, Sood AK, Conzen SD, Hortobagyi GN, Gonzalez-Angulo AM. Beta-Blocker Use Is Associated With Improved Relapse-Free Survival in Patients With Triple-Negative Breast Cancer. J Clin Oncol 29(19):2645-52, 7/2011. e-Pub 5/2011. PMCID: PMC3139371.
36. Hernandez-Aya LF, Chavez-MacGregor M, Lei X, Meric-Bernstam F, Buchholz TA, Hsu L, Sahin AA, Do KA, Valero V, Hortobagyi GN, Gonzalez-Angulo AM. Nodal status and clinical outcomes in a large cohort of patients with triple-negative breast cancer. J Clin Oncol 29(19):2628-34, 7/2011. e-Pub 5/2011. PMCID: PMC3139370.
37. Xiao C, Gong Y, Han EY, Gonzalez-Angulo AM, Sneige N. Stability of HER2-positive status in breast carcinoma: a comparison between primary and paired metastatic tumors with regard to the possible impact of intervening trastuzumab treatment. Ann Oncol 22(7):1547-53, 7/2011. e-Pub 1/14/2011. PMID: 21239403.
38. Gonzalez-Angulo AM, Ferrer-Lozano J, Stemke-Hale K, Sahin A, Liu S, Barrera JA, Burgues O, Lluch AM, Chen H, Hortobagyi GN, Mills GB, Meric-Bernstam F. PI3K Pathway Mutations and PTEN Levels in Primary and Metastatic Breast Cancer. Mol Cancer Ther 10(6):1093-101, 6/2011. e-Pub 4/13/2011. PMCID: PMC3112276.
39. Dawood S, Ueno NT, Valero V, Woodward WA, Buchholz TA, Hortobagyi GN, Gonzalez-Angulo AM, Cristofanilli M. Differences in survival among women with stage III inflammatory and non-inflammatorylocally advanced breast cancer appear early: A large population based study. Cancer 117(9):1819-26, 5/1/2011. e-Pub 11/29/2010. PMID: 21509759.
40. Mittendorf EA, Jeruss JS, Tucker SL, Kolli A, Newman LA, Gonzalez-Angulo AM, Buchholz TA, Sahin AA, Cormier JN, Buzdar AU, Hortobagyi GN, Hunt KK. Validation of a novel staging system for disease-specific survival in patients with breast cancer treated with neoadjuvant chemotherapy. J Clin Oncol 29(15):1956-62, 5/20/2011. e-Pub 4/11/2011. PMCID: PMC3107758.
41. Albert JM, Gonzalez-Angulo AM, Guray M, Sahin A, Tereffe W, Woodward WA, Strom EA, Hunt KK, Tucker SL, Buchholz TA. Patients with only 1 positive hormone receptor have increased locoregional recurrence compared with patients with estrogen receptor-positive progesterone receptor-positive disease in very early stage breast cancer. Cancer 117(8):1595-601, 4/15/2011. e-Pub 11/8/2010. PMID: 21472707.
42. Rexer BN, Ham AJ, Rinehart C, Hill S, de Matos Granja-Ingram N, González-Angulo AM, Mills GB, Dave B, Chang JC, Liebler DC, Arteaga CL. Phosphoproteomic mass spectrometry profiling links Src family kinases to escape from HER2 tyrosine kinase inhibition. Oncogene. e-Pub 4/18/2011. PMID: 21499296.
43. Miller TW, Balko JM, Ghazoui Z, Dunbier A, Anderson H, Dowsett M, Gonzalez-Angulo AM, Mills GB, Miller WR, Wu H, Shyr Y, Arteaga CL. A Gene Expression Signature from Human Breast Cancer Cells with Acquired Hormone Independence Identifies MYC as a Mediator of Antiestrogen Resistance. Clin Cancer Res 17(7):2024-34, 4/2011. e-Pub 2/2011. PMCID: PMC3221728.
44. Caudle AS, Gonzalez-Angulo AM, Hunt KK, Pusztai L, Kuerer HM, Mittendorf EA, Hortobagyi GN, Meric-Bernstam F. Impact of Progression During Neoadjuvant Chemotherapy on Surgical Management of Breast Cancer. Ann Surg Oncol 18(4):932-8, 4/2011. e-Pub 11/2010. PMID: 21061075.
45. Gonzalez-Angulo AM, Timms KM, Liu S, Chen H, Litton JK, Potter J, Lanchbury JS, Stemke-Hale K, Hennessy BT, Arun BK, Hortobagyi GN, Do KA, Mills GB, Meric-Bernstam F. Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer. Clin Cancer Res 17(5):1082-9, 3/1/2011. e-Pub 1/13/2011. PMCID: PMC3048924.
46. Yi M, Buchholz TA, Meric-Bernstam F, Bedrosian I, Hwang RF, Ross MI, Kuerer HM, Luo S, Gonzalez-Angulo AM, Buzdar AU, Symmans WF, Feig BW, Lucci A, Huang EH, Hunt KK. Classification of Ipsilateral Breast Tumor Recurrences After Breast Conservation Therapy can Predict Patient Prognosis and Facilitate Treatment Planning. Ann Surg 253(3):572-9, 3/2011. e-Pub 1/2011. PMID: 21209588.
47. Ghosh R, Narasanna A, Wang SE, Liu S, Chakrabarty A, Balko JM, Gonzalez-Angulo AM, Mills GB, Penuel E, Winslow J, Sperinde J, Dua R, Pidaparthi S, Mukherjee A, Leitzel K, Kostler WJ, Lipton A, Bates M, Arteaga CL. Trastuzumab has preferential activity against breast cancers driven by HER2 homodimers. Cancer Res 71(5):1871-82, 3/2011. e-Pub 2/2011. PMCID: PMC3221734.
48. Gonzalez-Angulo AM, Hennessy BT, Meric-Bernstam F, Sahin A, Liu W, Ju Z, Carey MS, Myhre S, Speers C, Deng L, Broaddus R, Lluch A, Aparicio S, Brown P, Pusztai L, Symmans WF, Alsner J, Overgaard J, Borresen-Dale AL, Hortobagyi GN, Coombes KR, Mills GB. Functional proteomics can define prognosis and predict pathologic complete response in patients with breast cancer. Clin Proteomics 8(1):11, 2011. e-Pub 7/8/2011. PMCID: PMC3170272.
49. Hayashi N, Iwamoto T, Gonzalez-Angulo AM, Ferrer-Lozano J, Lluch A, Niikura N, Bartholomeusz C, Nakamura S, Hortobagyi GN, Ueno NT. Prognostic impact of phosphorylated HER-2 in HER-2+ primary breast cancer. Oncologist 16(7):956-65, 2011. e-Pub 6/28/2011. PMCID: PMC3228141.
50. Li J, Gonzalez-Angulo AM, Allen PK, Yu TK, Woodward WA, Ueno NT, Lucci A, Krishnamurthy S, Gong Y, Bondy ML, Yang W, Willey JS, Cristofanilli M, Valero V, Buchholz TA. Triple-Negative Subtype Predicts Poor Overall Survival and High Locoregional Relapse in Inflammatory Breast Cancer. Oncologist 16(12):1675-83, 2011. e-Pub 12/6/2011. PMCID: PMC3248766.
51. Hennessy BT, Lu Y, Gonzalez-Angulo AM, Carey MS, Myhre S, Ju Z, Davies MA, Liu W, Coombes K, Meric-Bernstam F, Bedrosian I, McGahren M, Agarwal R, Zhang F, Overgaard J, Alsner J, Neve RM, Kuo WL, Gray JW, Borresen-Dale AL, Mills GB. A technical assessment of the utility of reverse phase protein arrays for the study of the functional proteome in non-microdissected human breast cancers. Clin Proteomics 6(4):129-151, 12/2010. PMCID: PMC3116520.
52. Kelly CM, Krishnamurthy S, Bianchini G, Litton JK, Gonzalez-Angulo AM, Hortobagyi GN, Pusztai L. Utility of Oncotype DX risk estimates in clinically intermediate risk hormone receptor-positive, HER2-normal, grade II, lymph node-negative breast cancers. Cancer 116(22):5161-7, 11/15/2010. e-Pub 7/27/2010. PMID: 20665886.
53. Sharma R, Bedrosian I, Lucci A, Hwang RF, Rourke LL, Qiao W, Buchholz TA, Kronowitz SJ, Krishnamurthy S, Babiera GV, Gonzalez-Angulo AM, Meric-Bernstam F, Mittendorf EA, Hunt KK, Kuerer HM. Present-Day Locoregional Control in Patients with T1 or T2 Breast Cancer with 0 and 1 to 3 Positive Lymph Nodes After Mastectomy Without Radiotherapy. Ann Surg Oncol 17(11):2899-908, 11/2010. e-Pub 5/5/2010. PMID: 20443145.
54. Luyimbazi D, Akcakanat A, McAuliffe PF, Zhang L, Singh G, Gonzalez-Angulo AM, Chen H, Do KA, Zheng Y, Hung MC, Mills GB, Meric-Bernstam F. Rapamycin Regulates Stearoyl CoA Desaturase 1 Expression in Breast Cancer. Mol Cancer Ther 9(10):2770-84, 10/2010. e-Pub 9/28/2010. PMCID: PMC2965451.
55. Cheng YC, Valero V, Davis ML, Green MC, Gonzalez-Angulo AM, Theriault RL, Murray JL, Hortobagyi GN, Ueno NT. Addition of GM-CSF to trastuzumab stabilises disease in trastuzumab-resistant HER2+ metastatic breast cancer patients. Br J Cancer. e-Pub 9/2010.
56. Chavez-MacGregor M, Litton J, Chen H, Giordano SH, Hudis CA, Wolff AC, Valero V, Hortobagyi GN, Bondy ML, Gonzalez-Angulo AM. Pathologic complete response in breast cancer patients receiving anthracycline- and taxane-based neoadjuvant chemotherapy: evaluating the effect of race/ethnicity. Cancer 116(17):4168-77, 9/2010. PMCID: PMC2954673.
57. Albert JM, Gonzalez-Angulo AM, Guray M, Sahin A, Strom EA, Tereffe W, Woodward WA, Tucker SL, Hunt KK, Hortobagyi GN, Buchholz TA. Estrogen/progesterone receptor negativity and HER2 positivity predict locoregional recurrence in patients with T1a,bN0 breast cancer. Int J Radiat Oncol Biol Phys 77(5):1296-302, 8/1/2010. e-Pub 5/14/2010. PMID: 20472353.
58. Hennessy BT, Timms KM, Carey MS, Gutin A, Meyer LA, Flake DD, Abkevich V, Potter J, Pruss D, Glenn P, Li Y, Li J, Gonzalez-Angulo AM, McCune KS, Markman M, Broaddus RR, Lanchbury JS, Lu KH, Mills GB. Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancer. J Clin Oncol 28(22):3570-6, 8/1/2010. e-Pub 7/6/2010. PMCID: PMC2917312.
59. Dawood S, Gonzalez-Angulo AM, Albarracin C, Yu TK, Hortobagyi GN, Buchholz TA, Woodward WA. Prognostic factors of survival in the trastuzumab era among women with breast cancer and brain metastases who receive whole brain radiotherapy: a single-institution review. Cancer 116(13):3084-92, 7/1/2010. PMCID: PMC3041268.
60. Dawood S, Gong Y, Broglio K, Buchholz TA, Woodward W, Lucci A, Valero V, Gonzalez-Angulo AM, Hortobagyi GN, Cristofanilli M. Trastuzumab in Primary Inflammatory Breast Cancer (IBC): High Pathological Response Rates and Improved Outcome. Breast J. e-Pub 7/6/2010. PMCID: PMC3097300.
61. Miller TW, Hennessy BT, Gonzalez-Angulo AM, Fox EM, Mills GB, Chen H, Higham C, García-Echeverría C, Shyr Y, Arteaga CL. Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor-positive human breast cancer. J Clin Invest 120(7):2406-13, 7/2010. e-Pub 6/2010. PMCID: PMC2898598.
62. Gonzalez-Angulo AM, Hennessy BT, Mills GB. Future of personalized medicine in oncology: a systems biology approach. J Clin Oncol 28(16):2777-83, 6/1/2010. e-Pub 4/20/2010. PMCID: PMC2881854.
63. Loi S, Haibe-Kains B, Majjaj S, Lallemand F, Durbecq V, Larsimont D, Gonzalez-Angulo AM, Pusztai L, Symmans WF, Bardelli A, Ellis P, Tutt AN, Gillett CE, Hennessy BT, Mills GB, Phillips WA, Piccart MJ, Speed TP, McArthur GA, Sotiriou C. PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancer. Proc Natl Acad Sci U S A 107(22):10208-13, 6/1/2010. e-Pub 5/17/2010. PMCID: PMC2890442.
64. Caudle AS, Gonzalez-Angulo AM, Hunt KK, Liu P, Pusztai L, Symmans WF, Kuerer HM, Mittendorf EA, Hortobagyi GN, Meric-Bernstam F. Predictors of tumor progression during neoadjuvant chemotherapy in breast cancer. J Clin Oncol 28(11):1821-8, 4/10/2010. e-Pub 3/15/2010. PMCID: PMC2860366.
65. Dogan BE, Gonzalez-Angulo AM, Gilcrease M, Dryden MJ, Yang WT. Multimodality imaging of triple receptor-negative tumors with mammography, ultrasound, and MRI. AJR Am J Roentgenol 194(4):1160-6, 4/2010. PMID: 20308526.
66. Woodward WA, Truong PT, Yu TK, Tereffe W, Oh J, Perkins G, Strom E, Meric-Bernstam F, Gonzalez-Angulo AM, Speers C, Ragaz J, Buchholz TA. Among women who experience a recurrence after postmastectomy radiation therapy irradiation is not associated with more aggressive local recurrence or reduced survival. Breast Cancer Res Treat. e-Pub 3/20/2010. PMID: 20306128.
67. Bartholomeusz C, Gonzalez-Angulo AM, Kazansky A, Krishnamurthy S, Liu P, Yuan LX, Yamasaki F, Liu S, Hayashi N, Zhang D, Esteva FJ, Hortobagyi GN, Ueno NT. PEA-15 inhibits tumorigenesis in an MDA-MB-468 triple-negative breast cancer xenograft model through increased cytoplasmic localization of activated extracellular signal-regulated kinase. Clin Cancer Res 16(6):1802-11, 3/15/2010. e-Pub 3/9/2010. PMID: 20215547.
68. Alvarez RH, Booser DJ, Cristofanilli M, Sahin AA, Strom EA, Guerra L, Kau SW, Gonzalez-Angulo AM, Hortobagyi GN, Valero V. Phase 2 trial of primary systemic therapy with doxorubicin and docetaxel followed by surgery, radiotherapy, and adjuvant chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil based on clinical and pathologic response in patients with stage IIB to III breast cancer : long-term results from The University of Texas M. D. Anderson Cancer Center Study ID97-099. Cancer 116(5):1210-7, 3/1/2010. e-Pub 1/2010. PMID: 20082452.
69. Creighton CJ, Fu X, Hennessy BT, Casa AJ, Zhang Y, Gonzalez-Angulo AM, Lluch A, Gray JW, Brown PH, Hilsenbeck SG, Osborne CK, Mills GB, Lee AV, Schiff R. Proteomic and transcriptomic profiling reveals a link between the PI3K pathway and lower estrogen-receptor (ER) levels and activity in ER+ breast cancer. Breast Cancer Res 12(3):R40, 2010. e-Pub 6/22/2010. PMCID: PMC2917035.
70. Gonzalez-Angulo AM, Litton JK, Broglio KR, Meric-Bernstam F, Rakkhit R, Cardoso F, Peintinger F, Hanrahan EO, Sahin A, Guray M, Larsimont D, Feoli F, Stranzl H, Buchholz TA, Valero V, Theriault R, Piccart-Gebhart M, Ravdin PM, Berry DA, Hortobagyi GN. High Risk of Recurrence for Patients With Breast Cancer Who Have Human Epidermal Growth Factor Receptor 2-Positive, Node-Negative Tumors 1 cm or Smaller. J Clin Oncol 27(34):5700-5706, 12/1/2009. e-Pub 11/2/2009. PMCID: PMC2792998.
71. Mittendorf EA, Wu Y, Scaltriti M, Meric-Bernstam F, Hunt KK, Dawood S, Esteva FJ, Buzdar AU, Chen H, Eksambi S, Hortobagyi GN, Baselga J, Gonzalez-Angulo AM. Loss of HER2 Amplification Following Trastuzumab-based Neoadjuvant Systemic Therapy and Survival Outcomes. Clin Cancer Res 15(23):7381-7388, 12/1/2009. e-Pub 11/17/2009. PMCID: PMC2788123.
72. Liedtke C, Broglio K, Moulder S, Hsu L, Kau SW, Symmans WF, Albarracin C, Meric-Bernstam F, Woodward W, Theriault RL, Kiesel L, Hortobagyi GN, Pusztai L, Gonzalez-Angulo AM. Prognostic impact of discordance between triple receptor measurements in primary and recurrent breast cancer. Ann Oncol 20(12):1953-8, 12/2009. e-Pub 7/12/2009. PMCID: PMC2791352.
73. Vasudevan KM, Barbie DA, Davies MA, Rabinovsky R, McNear CJ, Kim JJ, Hennessy BT, Tseng H, Pochanard P, Kim SY, Dunn IF, Schinzel AC, Sandy P, Hoersch S, Sheng Q, Gupta PB, Boehm JS, Reiling JH, Silver S, Lu Y, Stemke-Hale K, Dutta B, Joy C, Sahin AA, Gonzalez-Angulo AM, Lluch A, Rameh LE, Jacks T, Root DE, Lander ES, Mills GB, Hahn WC, Sellers WR, Garraway LA. AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer. Cancer Cell 16(1):21-32, 7/7/2009. PMCID: PMC2752826.
74. Jiralerspong S, Palla SL, Giordano SH, Meric-Bernstam F, Liedtke C, Barnett CM, Hsu L, Hung MC, Hortobagyi GN, Gonzalez-Angulo AM. Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. J Clin Oncol 27(20):3297-3302, 7/10/2009. e-Pub 6/1/2009. PMCID: PMC2736070.
75. Agarwal R, Gonzalez-Angulo AM, Myhre S, Carey M, Lee JS, Overgaard J, Alsner J, Stemke-Hale K, Lluch A, Neve RM, Kuo WL, Sorlie T, Sahin A, Valero V, Keyomarsi K, Gray JW, Borresen-Dale AL, Mills GB, Hennessy BT. Integrative analysis of cyclin protein levels identifies cyclin B1 as a classifier and predictor of outcomes in breast cancer. Clin Cancer Res 15(11):3654-3662, 6/1/2009. e-Pub 5/26/2009. PMCID: PMC2887710.
76. Cabioglu N, Sahin AA, Morandi P, Meric-Bernstam F, Islam R, Lin HY, Bucana CD, Gonzalez-Angulo AM, Hortobagyi GN, Cristofanilli M. Chemokine receptors in advanced breast cancer: differential expression in metastatic disease sites with diagnostic and therapeutic implications. Ann Oncol 20(6):1013-1019, 6/2009. e-Pub 2/23/2009. PMID: 19237480.
77. Miller TW, Pérez-Torres M, Narasanna A, Guix M, Stĺl O, Pérez-Tenorio G, Gonzalez-Angulo AM, Hennessy BT, Mills GB, Kennedy JP, Lindsley CW, Arteaga CL. Loss of Phosphatase and Tensin homologue deleted on chromosome 10 engages ErbB3 and insulin-like growth factor-I receptor signaling to promote antiestrogen resistance in breast cancer. Cancer Res 69(10):4192-201, 5/15/2009. e-Pub 5/12/2009. PMCID: PMC2724871.
78. Meric-Bernstam F, Gonzalez-Angulo AM. Targeting the mTOR Signaling Network for Cancer Therapy. J Clin Oncol 27(13):2278-2287, 5/1/2009. e-Pub 3/30/2009. PMCID: PMC2738634.
79. Hennessy BT, Gonzalez-Angulo AM, Stemke-Hale K, Gilcrease MZ, Krishnamurthy S, Lee JS, Fridlyand J, Sahin A, Agarwal R, Joy C, Liu W, Stivers D, Baggerly K, Carey M, Lluch A, Monteagudo C, He X, Weigman V, Fan C, Palazzo J, Hortobagyi GN, Nolden LK, Wang NJ, Valero V, Gray JW, Perou CM, Mills GB. Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics. Cancer Res 69(10):4116-24, 5/2009. e-Pub 5/2009. PMCID: PMC2737191.
80. Gonzalez-Angulo AM, Stemke-Hale K, Palla SL, Carey M, Agarwal R, Meric-Berstam F, Traina TA, Hudis C, Hortobagyi GN, Gerald WL, Mills GB, Hennessy BT. Androgen receptor levels and association with PIK3CA mutations and prognosis in breast cancer. Clin Cancer Res 15(7):2472-8, 4/1/2009. e-Pub 3/10/2009. PMID: 19276248.
81. Litton JK, Westin SN, Ready K, Sun CC, Peterson SK, Meric-Bernstam F, Gonzalez-Angulo AM, Bodurka DC, Lu KH, Hortobagyi GN, Arun BK. Perception of screening and risk reduction surgeries in patients tested for a BRCA deleterious mutation. Cancer 115(8):1598-604, 4/15/2009. PMCID: PMC2680417.
82. Dawood S, Broglio K, Esteva FJ, Yang W, Kau SW, Islam R, Albarracin C, Yu TK, Green M, Hortobagyi GN, Gonzalez-Angulo AM. Survival among women with triple receptor-negative breast cancer and brain metastases. Ann Oncol 20(4):621-7, 4/2009. e-Pub 1/15/2009. PMCID: PMC2722369.
83. Carkaci S, Macapinlac HA, Cristofanilli M, Mawlawi O, Rohren E, Gonzalez Angulo AM, Dawood S, Resetkova E, Le-Petross HT, Yang WT. Retrospective study of 18F-FDG PET/CT in the diagnosis of inflammatory breast cancer: preliminary data. J Nucl Med 50(2):231-8, 2/2009. e-Pub 1/21/2009. PMID: 19164229.
84. Dawood S, Broglio K, Kau SW, Green MC, Giordano SH, Meric-Bernstam F, Buchholz TA, Albarracin C, Yang WT, Hennessy BT, Hortobagyi GN, Gonzalez-Angulo AM. Triple receptor-negative breast cancer: The effect of race on response to primary systemic treatment and survival outcomes. J Clin Oncol 27(2):220-226, 1/10/2009. e-Pub 12/1/2008. PMID: 19047281.
85. Peintinger F, Buzdar AU, Kuerer HM, Mejia JA, Hatzis C, Gonzalez-Angulo AM, Pusztai L, Esteva FJ, Dawood SS, Green MC, Hortobagyi GN, Symmans WF. Hormone receptor status and pathologic response of HER2-positive breast cancer treated with neoadjuvant chemotherapy and trastuzumab. Ann Oncol 19(12):2020-5, 12/2008. e-Pub 7/29/2008. PMCID: PMC2733116.
86. Gonzalez-Angulo AM, Walters R, Broglio K, Frye DK, Strom EA, Theriault RL, Booser DJ, Valero V, Buzdar AU, Hortobagyi GN. Using response to primary chemotherapy to select postoperative therapy: long-term results from a prospective phase II trial in locally advanced primary breast cancer. Clin Breast Cancer 8(6):516-21, 12/2008. PMID: 19073507.
87. Dawood S, Broglio K, Gonzalez-Angulo AM, Buzdar AU, Hortobagyi GN, Giordano SH. Trends in survival over the past two decades among white and black patients with newly diagnosed stage IV breast cancer. J Clin Oncol 26(30):4891-8, 10/20/2008. e-Pub 8/25/2008. PMCID: PMC2736998.
88. Atchley DP, Albarracin CT, Lopez A, Valero V, Amos CI, Gonzalez-Angulo AM, Hortobagyi GN, Arun BK. Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer. J Clin Oncol 26(26):4282-8, 9/10/2008. PMID: 18779615.
89. Litton JK, Gonzalez-Angulo AM, Warneke CL, Buzdar AU, Kau SW, Bondy M, Mahabir S, Hortobagyi GN, Brewster AM. Relationship between obesity and pathologic response to neoadjuvant chemotherapy among women with operable breast cancer. J Clin Oncol 26(25):4072-7, 9/1/2008. PMID: 18757321.
90. Stemke-Hale K, Gonzalez-Angulo AM, Lluch A, Neve RM, Kuo WL, Davies M, Carey M, Hu Z, Guan Y, Sahin A, Symmans WF, Pusztai L, Nolden LK, Horlings H, Berns K, Hung MC, van de Vijver MJ, Valero V, Gray JW, Bernards R, Mills GB, Hennessy BT. An integrative genomic and proteomic analysis of PIK3CA, PTEN and AKT mutations in breast cancer. Cancer Res 68(15):6084-6091, 8/1/2008. PMCID: PMC2680495.
91. Jeruss JS, Mittendorf EA, Tucker SL, Gonzalez-Angulo AM, Buchholz TA, Sahin AA, Cormier JN, Buzdar AU, Hortobagyi GN, Hunt KK. Staging of breast cancer in the neoadjuvant setting. Cancer Res 68(16):6477-81, 8/15/2008. PMID: 18701468.
92. Dawood S, Resetkova E, Gonzalez-Angulo AM. Trastuzumab administration associated with change in HER-2 status. Clin Breast Cancer 8(4):366-369, 8/2008. PMID: 18757266.
93. Dawood S, Broglio K, Esteva FJ, Ibrahim NK, Kau SW, Islam R, Aldape KD, Yu TK, Hortobagyi GN, Gonzalez-Angulo AM. Defining prognosis for women with breast cancer and CNS metastases by HER2 status. Ann Oncol 19(7):1242-8, 7/2008. e-Pub 3/11/2008. PMID: 18334512.
94. Soni A, Akcakanat A, Singh G, Luyimbazi D, Zheng Y, Kim D, Gonzalez-Angulo A, Meric-Bernstam F. eIF4E knockdown decreases breast cancer cell growth without activating Akt signaling. Mol Cancer Ther 7(7):1782-8, 7/2008. PMCID: PMC2559956.
95. Yang WT, Le-Petross HT, Macapinlac H, Carkaci S, Gonzalez-Angulo AM, Dawood S, Resetkova E, Hortobagyi GN, Cristofanilli M. Inflammatory Breast Cancer - PET/CT, MRI, Mammography, and Sonography Findings. Breast Cancer Res Treat 109(3):417-26, 6/2008. e-Pub 7/26/2007. PMID: 17653852.
96. Dawood S, Broglio K, Gong Y, Yang WT, Cristofanilli M, Kau SW, Meric-Bernstam F, Buchholz TA, Hortobagyi GN, Gonzalez-Angulo AM, Inflammatory Breast Cancer Research Group. Prognostic significance of HER-2 status in women with inflammatory breast cancer. Cancer 112(9):1905-11, 5/1/2008. PMID: 18300243.
97. Dawood S, Broglio K, Gonzalez-Angulo AM, Kau SW, Islam R, Hortobagyi GN, Cristofanilli M. Prognostic value of Body Mass Index (BMI) in Locally Advanced Breast Cancer (LABC). Clin Cancer Res 14(6):1718-25, 3/15/2008. PMID: 18347172.
98. Liedtke C, Mazouni C, Hess KR, André F, Tordai A, Mejia JA, Symmans WF, Gonzalez-Angulo AM, Hennessy B, Green M, Cristofanilli M, Hortobagyi GN, Pusztai L. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol 10(8):1275-1281, 3/10/2008. e-Pub 2/4/2008. PMID: 18250347.
99. Andre F, Mazouni C, Liedtke C, Kau SW, Frye D, Green M, Gonzalez-Angulo AM, Symmans WF, Hortobagyi GN, Pusztai L. HER2 expression and efficacy of preoperative paclitaxel/FAC chemotherapy in breast cancer. Breast Cancer Res Treat 108(2):183-190, 3/2008. e-Pub 4/28/2007. PMID: 17468948.
100. Jeruss JS, Mittendorf EA, Tucker SL, Gonzalez-Angulo AM, Buchholz TA, Sahin AA, Cormier JN, Buzdar AU, Hortobagyi GN, Hunt KK. The combined use of clinical and pathologic staging variables to define outcomes for breast cancer patients treated with neoadjuvant therapy. J Clin Oncol 26(2):246-52, 1/10/2008. e-Pub 12/3/2007. PMID: 18056680.
101. Dawood S, Broglio K, Gonzalez-Angulo AM, Kau SW, Yang W, Albarracin C, Meric F, Hortobagyi G, Theriault R. Development of new cancers in patients with DCIS: The M.D. Anderson Experience. Ann Surg Oncol 15(1):244-249, 1/2008. e-Pub 11/28/2007. PMID: 18043978.
102. Dawood S, Broglio K, Kau SW, Islam R, Symmans WF, Buchholz TA, McGuire SE, Meric-Bernstam F, Cristofanilli M, Hortobágyi GN, Gonzalez-Angulo AM. Prognostic Value of Initial Clinical Disease Stage after achieving Pathological Complete Response. Oncologist 13(1):6-15, 1/2008. PMID: 18245008.
103. Hennessy BT, Lu Y, Poradosu E, Yu Q, Yu S, Hall H, Carey MS, Ravoori M, Gonzalez-Angulo AM, Birch R, Henderson IC, Kundra V, Mills GB. Pharmacodynamic markers of perifosine efficacy. Clin Cancer Res 13(24):7421-7431, 12/15/2007. PMID: 18094426.
104. Hennessy BT, Gilcrease MZ, Kim E, Gonzalez-Angulo AM. Breast Carcinoma with Neuroendocrine Differentiation and Myocardial Metastases. Clin Breast Cancer 7(11):892-4, 12/2007. PMID: 18269781.
105. Beinart G, Gonzalez-Angulo AM, Broglio K, Mejia J, Ruggeri A, Mininberg E, Hortobagyi GN, Valero V. Clinical course of 771 patients with bilateral breast cancer: characteristics associated with overall and recurrence-free survival. Clin Breast Cancer 7(11):867-74, 12/2007. PMID: 18269777.
106. Hanrahan EO, Gonzalez-Angulo AM, Giordano SH, Rouzier R, Broglio KR, Hortobagyi GN, Valero V. Overall survival and cause-specific mortality of patients with stage T1a,bN0M0 breast carcinoma. J Clin Oncol 25(31):4952-60, 11/1/2007. PMID: 17971593.
107. Morales-Vásquez F, Gonzalez-Angulo AM, Broglio K, Lopez-Basave HN, Gallardo D, Hortobagyi GN, De La Garza JG. Adjuvant Chemotherapy with Doxorubicin and Dacarbazine Has No Effect in Recurrence-Free Survival of Malignant Phyllodes Tumors of the Breast. Breast J 13(6):551-556, Nov-Dec, 11/2007. PMID: 17983394.
108. Cristofanilli M, Valero V, Buzdar AU, Kau SW, Broglio KR, Gonzalez-Angulo AM, Sneige N, Islam R, Ueno NT, Buchholz TA, Singletary SE, Hortobagyi GN. Inflammatory breast cancer (IBC) and patterns of recurrence: understanding the biology of a unique disease. Cancer 110(7):1436-1444, 10/1/2007. PMID: 17694554.
109. Litton JK, Eralp Y, Gonzalez-Angulo AM, Broglio K, Uyei A, Hortobagyi GN, Arun B. Multifocal breast cancer in women < or =35 years old. Cancer 110(7):1445-50, 10/1/2007. PMID: 17676585.
110. Berns K, Horlings HM, Hennessy BT, Madiredjo M, Hijmans EM, Beelen K, Linn SC, Gonzalez-Angulo AM, Stemke-Hale K, Hauptmann M, Beijersbergen RL, Mills GB, van de Vijver MJ, Bernards R. A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 12(4):395-402, 10/2007. PMID: 17936563.
111. Dawood S, Gonzalez-Angulo AM, Peintinger F, Broglio K, Symmans WF, Kau SW, Islam R, Hortobagyi GN, Buzdar AU. Efficacy and safety of neoadjuvant trastuzumab combined with paclitaxel and epirubicin: a retrospective review of the M. D. Anderson experience. Cancer 110(6):1195-200, 9/15/2007. PMID: 17647266.
112. Hwang RF, Gonzalez-Angulo AM, Yi M, Buchholz TA, Meric-Bernstam F, Kuerer HM, Babiera GV, Tereffe W, Liu DD, Hunt KK. Low local-regional failure rates in selected breast cancer patients with tumor positive sentinel lymph nodes who do not undergo completion axillary dissection. Cancer 110(4):723-30, 8/15/2007. PMID: 17587208.
113. Gonzalez-Angulo AM, Hennessy BT, Broglio K, Meric-Bernstam F, Cristofanilli M, Giordano SH, Buchholz TA, Sahin A, Singletary SE, Buzdar AU, Hortobágyi GN. Trends for inflammatory breast cancer: Is survival improving? Oncologist 12(8):904-12, 8/2007. PMID: 17766649.
114. McGuire SE, Gonzalez-Angulo AM, Huang EH, Tucker SL, Kau SW, Yu TK, Strom EA, Oh JL, Woodward WA, Tereffe W, Hunt KK, Kuerer HM, Sahin AA, Hortobagyi GN, Buchholz TA. Post-mastectomy radiation improves the outcome of patients with stage III breast cancer who achieve a pathologic complete response to neoadjuvant chemotherapy. Int J Radiat Oncol Biol Phys 68(4):1004-9, 7/15/2007. e-Pub 4/6/2007. PMID: 17418973.
115. Sher T, Hennessy BT, Valero V, Broglio K, Woodward WA, Trent J, Hunt KK, Hortobagyi GN, Gonzalez-Angulo AM. Primary Angiosarcomas of the Breast. Cancer 110(1):173-178, 7/1/2007. PMID: 17541936.
116. Mazouni C, Peintinger F, Wan-Kau S, Andre F, Gonzalez-Angulo AM, Symmans WF, Meric-Bernstam F, Valero V, Hortobagyi GN, Pusztai L. Residual DCIS in patients with complete eradication of invasive breast cancer after neoadjuvant chemotherapy does not adversely affect patient outcome. J Clin Oncol 25(19):2650-5, 7/1/2007. PMID: 17602071.
117. Cabioglu N, Gong Y, Islam R, Broglio KR, Sneige N, Sahin A, Gonzalez-Angulo AM, Morandi P, Bucana C, Hortobagyi GN, Cristofanilli M. Expression of growth factor and chemokine receptors: new insights in the biology of inflammatory breast cancer. Ann Oncol 18(6):1021-1029, 6/2007. e-Pub 3/9/2007. PMID: 17351259.
118. Beinart GA, Gonzalez-Angulo AM, Broglio K, Frye D, Walters R, Holmes FA, Gunale S, Booser D, Rosenthal J, Dhingra K, Young JA, Hortobagyi GN. Phase II trial of 10-EDAM in the treatment of metastatic breast cancer. Cancer Chemother Pharmacol 60(1):61-67, 6/2007. e-Pub 9/29/2006. PMID: 17009032.
119. Mazouni C, Kau SW, Frye D, Andre F, Kuerer HM, Buchholz TA, Symmans WF, Anderson K, Hess KR, Gonzalez-Angulo AM, Hortobagyi GN, Buzdar AU, Pusztai L. Inclusion of taxanes, particularly weekly paclitaxel, in preoperative chemotherapy improves pathologic complete response rate in estrogen receptor-positive breast cancers. Ann Oncol 18(5):874-880, 5/2007. e-Pub 2/10/2007. PMID: 17293601.

Invited Articles

1. Meng X, Zhong J, Liu S, Murray M, Gonzalez-Angulo AM. A new hypothesis for the cancer mechanism. Cancer Metastasis Rev 31(1-2):247-68, 6/2012. e-Pub 12/17/2011. PMCID: PMC3350627.
2. Bartholomeusz C, Gonzalez-Angulo AM. Targeting the PI3K signaling pathway in cancer therapy. Expert Opin Ther Targets 16(1):121-30, 1/2012. e-Pub 1/12/2012. PMID: 22239433.
3. Tabchy A, Hennessy BT, Gonzalez-Angulo AM, Bernstam FM, Lu Y, Mills GB. Quantitative Proteomic Analysis in Breast Cancer. Drugs Today (Barc) 47(2):169-82, 2/2011. PMID: 21431104.
4. Whitman GJ, Albarracin CT, Gonzalez-Angulo AM. Triple negative Breast Cancer: What the radiologist needs to know. Semin Roentgenol 46(1):26-39, 1/2011. PMID: 21134526.
5. Hernandez-Aya LF, Gonzalez-Angulo AM. Targeting the phosphatidylinositol 3-kinase signaling pathway in breast cancer. Oncologist 16(4):404-14, 2011. e-Pub 3/15/2011. PMCID: PMC3228119.
6. Gonzalez-Angulo AM. Importance of Accurate HER2 Testing in Patients with Metastatic Breast Cancer. Clin Adv Hematol Oncol 8(12):873-4, 12/2010. PMID: 21326164.
7. McAuliffe PF, Meric-Bernstam F, Mills GB, Gonzalez-Angulo AM. Deciphering the role of PI3K/Akt/mTOR pathway in breast cancer biology and pathogenesis. Clin Breast Cancer 10:S59-65, 11/2010. PMID: 21115423.
8. Chávez-MacGregor M, González-Angulo AM. Breast cancer, neoadjuvant chemotherapy and residual disease. Clin Transl Oncol 12(7):461-7, 7/2010. PMID: 20615822.
9. Gonzalez-Angulo AM, Meric-Bernstam F. Metformin: a therapeutic opportunity in breast cancer. Clin Cancer Res 16(6):1695-700, 3/15/2010. e-Pub 3/9/2010. PMCID: PMC2840206.
10. Gonzalez-Angulo AM. Defining the lower limit of risk, stage or tumor size for trastuzumab-based adjuvant chemotherapy for HER2+ breast cancer. Breast Disease: A Year Book Quarterly 21:112-115, 2010.
11. Liedtke C, Gonzalez-Angulo AM, Pusztai L. Definition of triple-negative breast cancer and relationship to basal-like molecular subtype. Principles and Practice of Oncology Updates, 2010.
12. Brown EN, Gonzalez-Angulo AM. Triple Receptor negative Breast Cancer: Current and Future Treatments. Contemporary Oncology 2:24-33, 2010.
13. Chavez-MacGregor M, Gonzalez-Angulo AM. HER2-neu positivity in patients with small and node-negative breast cancer (pT1a,b, N0,M0): a high-risk group? Clin Adv Hematol Oncol 7(9):591-598, 9/2009. PMID: 20020671.
14. Litton JK, Theriault RL, Gonzalez-Angulo AM. Breast cancer diagnosis during pregnancy. Womens Health (Lond Engl) 5(3):243-249, 5/2009. PMCID: PMC2753540.
15. Sanchez-Navarro JP, Gonzalez-Angulo AM. Cancer de mama triple receptor negativo. Rev Fac Med U Militar Nueva Granada 10:192-199, 2008.
16. Gonzalez-Angulo AM. Advances in triple receptor-negative breast cancer. Clin Adv Hematol Oncol 5(12):956-7, 12/2007. PMID: 18277956.
17. Gonzalez-Angulo AM, Dawood S, Cristofanilli M. Células Tumorales Circulantes y Manejo del Cáncer de Mama. Avances Cientificos Oncologia 2:4-9, 2007.
18. Gonzalez-Angulo AM, Morales-Vasquez F, Hortobagyi GN. Overview of resistance to systemic therapy in patients with breast cancer. Adv Exp Med Biol 608:1-22, 2007. PMID: 17993229.

Editorials

1. Pollak M, Gonzalez-Angulo AM. Metformin and hepatic carcinogenesis. Cancer Prev Res (Phila) 5(4):500-2, 4/2012. e-Pub 3/31/2012. PMID: 22467079.

Letters to the Editor

1. Caudle AS, Gonzalez-Angulo AM, Meric-Bernstam F. Reply: Strategy for Nonresponder Breast Cancer Patients to Neoadjuvant Treatment. Ann Surg Oncol. e-Pub 8/2011. PMID: 21826559.
2. Gonzalez-Angulo AM. Replies to "High risk of recurrence for breast cancer patients with HER2-positive node negative tumors 1 cm or smaller" by Roukos et al and Schinagle et al. J Clin Oncol:e282-e283, 2010.
3. Dawood S, Gonzalez-Angulo AM. Reply to "African American women who received primary anthracycline and taxane-based chemotherapy for triple-negative breast cancer suffer worse outcomes compared to Causasian women" by Ani Balmanoukian, et al. J Clin Oncol 27:e38-e39, 2009.
4. Jiralerspong S, Gonzalez-Angulo AM. "Reply to Metaformin and pathologic complete response to neoadjuvant chemotherapy in diabetic patients with breast cancer" by A. Garcia, et al. J Clin Oncol 27:e260, 2009.
5. Jiralerspong S, Gonzalez-Angulo AM. Reply to "Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer" by T. Grenader, et al. J Clin Oncol 27:DOI:10.1200, 2009.

Grant & Contract Support

Title: Identification of mechanisms to deal with resistance to targeted therapies
Funding Source: MDACC
Role: Co-Principal Investigator
Principal Investigator: Mendelsohn/Gonzalez-Angulo
Duration: 1/1/2012 - 12/31/2016
 
Title: Akt Inhibitor MK-2206 for Breast Cancers with a PI3KCA Mutation and/or PTEN loss
Funding Source: NIH/NCI
Role: Co-Principal Investigator
Principal Investigator: Funda Meric-Bernstam
Duration: 9/1/2011 - 8/31/2013
 
Title: Frequency and outcome of BRCA1/2 mutations in Jordanian patients treated at KHCC
Funding Source: Sister Institute Network Fund
Role: Co-Principal Investigator
Duration: 8/1/2011 - 7/31/2012
 
Title: Personalized Therapy of Residual Breast Cancer after Neoadjuvant Treatment
Funding Source: American Cancer Society (ACS)
Role: Principal Investigator
Duration: 7/1/2011 - 6/30/2015
 
Title: A phase III, randomized clinical trial of standard adjuvant endocrine therapy +/- chemotherapy in patients with 1-3 positive nodes, hormone-receptor positive and her2-negative breast cancer with recurrence score (RS) of 25 or less
Funding Source: NCI/BIQSFP
Role: Principal Investigator
Duration: 1/1/2011 - 12/31/2016
 
Title: A phase III, randomized clinical trial of standard adjuvant endocrine therapy +/- chemotherapy in patients with 1-3 positive nodes, hormone-receptor positive and her2-negative breast cancer with recurrence score (RS) of 25 or less
Funding Source: Breast Cancer Research Foundation
Role: Principal Investigator
Duration: 10/1/2010 - 9/30/2013
 
Title: Targeting the P13K Pathway in Women's Cancers
Funding Source: American Association for Cancer Research (AACR)
Role: Co-Investigator
Principal Investigator: Cantley, Mills, Sawyers
Duration: 9/1/2009 - 8/30/2012
 
Title: Chemotherapy Resistance in Hispanic and African American Patients
Funding Source: Komen for the Cure Catalystic Award for Disparities
Role: Principal Investigator
Duration: 8/1/2009 - 7/31/2012
 
Title: Developing Effective Therapies for ER-negative Breast Cancer using Genomics and Proteomics
Funding Source: Susan G. Komen Breast Cancer Foundation
Role: Co-Investigator (Years 3 and 4)
Principal Investigator: Brown
Duration: 5/22/2008 - 5/21/2013
 
Title: A phase I-II, randomized open label clinical trial of fulvestrant versus the combination of fulvestrant and PI3K and Src pathways inhibitors as first-line therapy for metastatic hormone receptor-positive HER2-negative breast cancer
Funding Source: Commonwealth Foundation for Cancer Research
Role: Principal Investigator
Duration: 5/1/2008 - 4/30/2013
 
Title: U10 Full Member Application Affiliated with SWOG
Funding Source: NIH/NCI
Role: Co-Principal Investigator
Principal Investigator: Eng
Duration: 7/26/2004 - 2/28/2014

Last updated: 6/11/2013